http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-989557-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e1886853aff6b63bb43c5557498d84c2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-48 |
| filingDate | 1962-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac9e1fd281199887f40b39f794602f29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06888b1b9665d4131ec78a0c500b0146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f2efe0f1e3670aa84fb17d4fb5a937 |
| publicationDate | 1965-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-989557-A |
| titleOfInvention | Hydroxylamine derivative and processes for making it |
| abstract | The invention comprises 3,4-dihydroxybenzyloxyamine and salts thereof with physiologically tolerable acids, and their preparation by (a) reacting at least three molecular proportions of hydrazine with a compound of the general formula <FORM:0989557/C2/1> (wherein R1 and R2 each represents an aliphatic or aromatic acyl group, or R1 and R2 together represent a carbonyl group), or (b) reacting hydrazine with a compound of the general formula <FORM:0989557/C2/2> (wherein R3 and R4 each represents an alkyl or aryl group), and hydrolysing off the R3-SO2-and R4-SO2- groups, optionally followed in either case by salt formation. The following intermediates are prepared from the starting materials indicated in parentheses: N - (3,4 - dibenzenesulphonyloxybenzyloxy)-phthalimide (4-methylcatechol, via 3,4-dibenzenesulphonyloxytoluene and 3,4-dibenzenesulphonyloxybenzyl bromide); N-(3,4-carbonyldioxybenzyloxy) - phthalimide (3,4 - carbonyldioxybenzyl chloride). The compounds of the invention may be used in the treatment of disorders attributable to abnormal levels of 5-hydroxytryptamine and/or catecholamines. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2117836-A1 |
| priorityDate | 1962-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.